Compare Huntington Bancshares Incorporated (HBAN) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Huntington Bancshares Incorporated vs IDEXX Laboratories, Inc. — how do they compare? Huntington Bancshares Incorporated trades at $15.32 (market cap $31.04B), while IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B). The key difference: IDEXX Laboratories, Inc. is the larger of the two by market cap, and Huntington Bancshares Incorporated pays a 4.04% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Huntington Bancshares Incorporated for 52 Days and IDEXX Laboratories, Inc. for 46 Days on average.
| HBAN | IDXX | |
|---|---|---|
Market Cap | $31.04B | $40.43B |
Volume | 23,864,172 | 692,164 |
Sector | Financials | Health |
52-Week High | $19.27 | $766.68 |
52-Week Low | $15.02 | $504.70 |
Typical Hold Time | 52 Days | 46 Days |
Enterprise Value | $49.57B | $41.32B |
Dividend Yield | 4.04% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Huntington Bancshares (HBAN) trades at $15.37, up 1.32% on the day, with a bearish technical signal from moving averages. The company reported mixed quarterly earnings, missing in Q4 2025 and Q2 2026 but beating in Q1 2026, with Q3 2026 results pending. Revenue grew to $8.13B in 2025, and the stock trades at a P/E of 11.82, below the industry average. Recent news highlights increased call option activity and a dividend declaration of $0.16 payable in October 2026.
HBAN offers value with a low P/E and strong net income margin of 24.77%, but faces headwinds from interest rate pressures and reduced 2027 earnings guidance. Analyst consensus is a Buy with a $19.60 price target, implying 27% upside, though technical indicators and recent institutional put buying suggest near-term caution. Key risks include margin compression and competitive lending pressures.
IDEXX Laboratories (IDXX) trades at $513.14, up 1.28% with strong fundamentals including 25.03% net income margin and 74.21% ROE. The stock shows bearish technical signals but maintains consistent earnings beats and analyst consensus of $665 price target. Recent acquisition of CoVetAI expands AI capabilities in veterinary workflow intelligence, supporting long-term growth framework.
Outlook remains positive with revenue growth accelerating to $4.3B in 2025 and projected $4.6B in 2026. Key risks include foreign exchange headwinds and weaker U.S. veterinary visits. The 56.5% buy rating from analysts suggests continued confidence in the company's diagnostic innovation pipeline and recurring revenue economics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Huntington Bancshares Incorporated
Huntington Bancshares is a regional bank holding company headquartered in Columbus, Ohio. The bank has a network of branches and ATMs across eight Midwestern states. Founded in 1866, Huntington National Bank and its affiliates provide consumer, small-business, commercial, treasury management, wealth management, brokerage, trust, and insurance services. Huntington also provides auto dealer, equipment finance, national settlement, and capital market services that extend beyond its core states.
Read more on HBAN →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
